MLL-rearranged infant ALL patients fare significantly worse than infant ALL patients who do not carry MLL translocations, with event-free survival rates of 30-40% vs. ~80%, respectively [2]. The gene discussed is KMT2A; the disease is acute lymphoblastic leukemia.